Literature DB >> 9950195

Renal function following combination chemotherapy with ifosfamide and cisplatin in patients with osteogenic sarcoma.

C Arndt1, B Morgenstern, D Hawkins, D Wilson, R Liedtke, J Miser.   

Abstract

BACKGROUND: Ifosfamide and cisplatin are active agents that are currently used in the treatment of osteosarcoma. Nephrotoxicity has been reported following their use in combination and alone. This study evaluates renal function in children and adolescents (median age 16 years) at least 3 months following completion of a chemotherapy regimen which included 54 g/m2 ifosfamide, 360 mg/m2 cisplatin, doxorubicin, and high-dose methotrexate. PROCEDURE: Mean glomerular filtration rate (GFR) was determined by inulin or iothalamate clearance; proximal tubular function was evaluated by measuring fractional excretion of glucose (FEglu), tubular maximum phosphate reabsorption per GFR (TMP/GFR), FE of urate, and 24-hour amino acid excretion. Distal tubular function was evaluated by 24-hour urinary calcium, FE of magnesium, and urinary osmolality after water deprivation. Twenty-four-hour urinary protein excretion was measured.
RESULTS: The mean GFR was 97 ml/min/1.73 m2. Although 10 of 24 patients had GFRs lower than normal, the lowest value was only 22% below the lower limit of normal and would not account for any clinical compromise. Proximal tubular function evaluation revealed normal FEglu, normal mean TMP/GFR values, and high FE of urate (1 5.7%). Two of twenty-four patients were shown to have mild generalized aminoaciduria. Distal tubular function evaluation showed normal 24-hour urinary calcium levels (mean 3.4 mg/kg) and FE of magnesium as well as normal urinary osmolality. Twenty-four-hour urinary protein excretion was normal in all patients.
CONCLUSIONS: The lack of clinically significant renal abnormalities observed in patients who received combination chemotherapy with ifosfamide and cisplatin for osteosarcoma is encouraging for future osteosarcoma protocol development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9950195     DOI: 10.1002/(sici)1096-911x(199902)32:2<93::aid-mpo4>3.0.co;2-y

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

Review 1.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

Review 2.  Ethical issues in including pediatric cancer patients in drug development trials.

Authors:  Katarina Aleksa; Gideon Koren
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies.

Authors:  Ingrid Lilienthal; Nikolas Herold
Journal:  Int J Mol Sci       Date:  2020-09-19       Impact factor: 5.923

4.  Pathophysiological mechanisms underlying a rat model of triple whammy acute kidney injury.

Authors:  Laura Prieto-García; Laura Vicente-Vicente; Víctor Blanco-Gozalo; Omar Hidalgo-Thomas; María C García-Macías; Armin Kurtz; Anita T Layton; Ana B Sanz; Ana I Morales; Carlos Martínez-Salgado; Miguel Pericacho; Sandra M Sancho-Martínez; Francisco J López-Hernández
Journal:  Lab Invest       Date:  2020-07-27       Impact factor: 5.662

Review 5.  Anticancer drug-induced kidney disorders.

Authors:  P E Kintzel
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.228

6.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.